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1. Introduction
1.1. Diagnostic criteria
In the late 1980s, a group of experts met in Rome to establish symptom-based diagnostic criteria
for functional gastrointestinal disorders (FGIDs). This first set of “Rome criteria,” published
in 1989, focused exclusively on adults [1]. In 1999, when these criteria were revised, a pediatric
committee established a parallel set of diagnostic criteria for FGIDs in children and adolescents
[2]. The Rome II pediatric subcommittee defined four pediatric disorders related to abdominal
pain: functional dyspepsia (FD), irritable bowel syndrome (IBS), abdominal migraine, and
functional abdominal pain. With Rome II, FD was defined as persistent or recurrent pain or
discomfort centered in the upper abdomen (above the umbilicus) that was unrelated to a
change in stool frequency or form and not exclusively relieved by defecation. Further, there
had to be no evidence of an inflammatory, anatomic, metabolic, or neoplastic process to explain
the patient’s symptoms. Importantly, the committee determined that mild, chronic inflamma‐
tory changes on mucosal biopsies should not preclude the diagnosis of FD. Similar to the adult
criteria on which they were based, the Rome II pediatric criteria for FD included 3 subtypes:
1) ulcer-like, in which pain was the predominant symptom; 2) dysmotility-like, in which
discomfort (e.g., bloating, early satiety, postprandial fullness) was the predominant symptom;
and, 3) unspecified.
In 2006, the same process of expert committees again revised the criteria, yielding the current
Rome III criteria [3,4]. In adults, the previous FD subtypes were eliminated while two new
subtypes were identified based on new studies generally utilizing factor analysis. The first
subtype, postprandial distress syndrome, was defined as bothersome postprandial fullness
occurring after ordinary sized meals and/or early satiation that prevents finishing a regular
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meal. The second subtype, epigastric pain syndrome, was defined as intermittent pain or
burning localized to the epigastrium (i.e., not generalized or localized to other abdominal or
chest regions) and of at least moderate severity. The Rome III pediatric subcommittee also
eliminated the old subtypes, but did not adopt the new adult subtypes because of a lack of
existing data to support their existence in children and adolescents. However, recent evidence
suggests that the adult subtypes actually may have meaningful associations with mucosal
inflammation and psychosocial functioning in pediatric FD [5].
1.2. Prevalence and presentation
Most pediatric gastroenterologists may not routinely use Rome criteria and differences exist
in how the criteria are interpreted. Nevertheless, there is agreement that a strong majority of
children with chronic abdominal pain presenting to pediatric gastroenterology practices fulfill
criteria for an FGID, with the two most common being FD and IBS [6-9]. Community preva‐
lence for FD is estimated at 3.5-27% in children/adolescents compared to 20-30% in adults [3,4].
In both pediatric and adult gastroenterology practices, FD frequently overlaps with IBS or
gastroesophageal reflux [7,10]. Adult IBS overlap is associated with more psychological
dysfunction including anxiety and depression, compared to “pure” FD, but this association
does not appear to be present in pediatric overlap [11,12]. Pediatric FD is associated with lower
quality of life, increased functional disability, and increased likelihood of meeting criteria for
an anxiety disorder relative to healthy children [13]. In adults with FD, the association with
anxiety appears to be specific to patients with postprandial distress syndrome, with this
relationship also apparent in children/adolescents with symptoms consistent with postpran‐
dial distress syndrome [5,14].
1.3. Etiology
FD, like all FGIDs, is probably best understood through a biopsychosocial model (see Figure
1). This model states that symptoms are likely the result of varying contributions from, and
interactions between, biological/physiological factors (e.g. inflammation, mechanical distur‐
bances, hypersensitivity), psychological factors (e.g. anxiety, depression, somatization), and
social factors (e.g. interactions with parents, teachers, or peers). Within this model, there is less
emphasis on the “cause” of symptoms than on “contributors” to its emergence and mainte‐
nance. This model would suggest that there is value in identifying and targeting all of the
factors which might be contributing to symptom generation in children with FD. It also would
suggest that there is value in understanding the mechanisms by which the factors interact with
one another, as these mechanisms represent additional opportunities for clinical intervention.
2. The role of inflammation in functional dyspepsia
Inflammation has the potential to contribute to the development of FGIDs via the release of
specific mediators that impact mechanisms known to play a role in the pathogenesis of these
conditions. Acute gastrointestinal inflammation and injury are associated with both peripheral
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and central sensitization of the nervous system, which results in visceral hyperalgesia [15].
Neuroplastic changes may occur that affect the response thresholds of enteric nerves, thereby
negatively impacting both sensitivity and motility [16]. Both motility and sensitivity responses
to acute inflammation in adults generally are reversible; however, animal model responses
suggest that, if inflammation occurs in neonates, neuroplastic changes and sensitivity may
persist into adulthood [17,18]. Visceral sensitization may be even more relevant in instances
where there is chronic inflammation with ongoing mediator release, as there may be subse‐
quent effects on visceral sensitivity that compound and prolong the issue.
Figure 1. The Biopsychosocial Model of FD
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The role of inflammation in FD has historically been controversial. However, emerging
evidence supports its role as a contributing factor in the biopsychosocial model of FD. In fact,
inflammation may be of particular importance in this model, as it interacts with a number of
other factors and may actually mediate the relationship between psychologic and physiologic
factors. The remainder of this chapter focuses on examination of inflammation within the
biopsychosocial model of FD, laying out the current evidence for its prevalence, mechanisms
of action, relationship with other important factors, and implications for evaluation and
treatment.
2.1. Chronic inflammation
Upper endoscopy is commonly performed in children with chronic abdominal pain in general
and children with functional dyspepsia in particular. Histologic inflammation is common in
these patients. In children with chronic abdominal pain, esophagitis is common and would
implicate gastroesophageal reflux as a contributor or cause of pain [19]. In one study of children
with FD, specifically, histologic esophagitis was found in 18%, gastritis in 21%, and duodenitis
in 13% [10]. Higher prevalences for gastritis, ranging from 43% to 71%, have been reported by
others [20,21]. For the broader group of children with chronic abdominal pain, histologic
inflammation has been documented in up to 79%, with an increase in mononuclear cells
(indicative of chronic inflammation) in the antrum of 55% and in the duodenum of 16% of
these children [19].
Most of these patients have chronic inflammation of which the clinical significance is unknown.
Chronic gastritis is not associated with electrogastrographic abnormalities, delayed gastric
emptying, or psychologic dysfunction in children with FD [5,22]. Despite this, chronic active
gastritis (manifest as lymphocytic and neutrophilic inflammation) has been associated with a
higher prevalence of nocturnal pain [21]. Chronic gastritis has been associated with an
increased prevalence of postprandial pain [5].
2.2. Mast cells
Increased mucosal mast cell density has been demonstrated in the gastric corpus and antrum
in adults with FD [23,24]. In adults with gastritis, mast cell density is significantly increased
and generally correlates with the intensity of the inflammation [25]. Though findings have
been variable, increased mast cell density appears isolated to the stomach in adults with FD;
increased duodenal mast cell density is more associated with IBS [24,26]. In addition, increased
mast cells in the proximal stomach in adults with FD have been associated with hypersensi‐
tivity; these mast cells will degranulate with balloon distension of the proximal stomach [27].
Due to a lack of normal control data, it is not known if gastric mast cells are elevated in pediatric
FD. However, antral mast cells do appear to be actively degranulating in children with FD,
with a mean degranulation index of 67% and greater than 50% degranulation in over 80% of
patients [28]. In children with FD, mast cell density positively correlates with slower gastric
emptying and increased gastric dysrhythmia (primarily preprandial bradycardia) in children
with FD [28]. Further, this dysrhythmia is associated with increased postprandial pain [29].
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2.3. Eosinophils
Ethical considerations preclude undertaking studies that assess eosinophil density in healthy
pediatric controls. However, the available pediatric literature indicates that it is reasonable to
consider eosinophil densities ≥10/hpf in the antrum and >20/hpf in the duodenum to be
abnormal. In a pediatric autopsy study, eosinophil density was <10/hpf in the antrum of all
subjects and ≤20/hpf in the duodenum of 82%, even though symptoms could not be docu‐
mented [30]. Another study reviewed biopsies from 682 presumably symptomatic children
referred for endoscopy, documenting eosinophil density ≤10/hpf in the antrum in 90% and
≤20/hpf in the duodenum in 93% [31].
While certain cut-off points for density seem reasonable, eosinophil density may not be
completely informative. Eosinophil biologic activity occurs through mediator release or
degranulation, and the effects are generally concentration-dependent. Important to consider
is the fact that density and activation are not correlated events [32]. In one study involving 20
children with FD, eosinophil density >20/hpf was present in only 15%; however, moderate to
extensive degranulation was demonstrated by electron microscopy in 95% [33].
Adult population studies have demonstrated increased duodenal eosinophil density in those
with dyspepsia compared to controls, whereas antral eosinophils did not differ between the
groups [34,35]. Higher eosinophil density and a higher prevalence of duodenal eosinophilia
(as defined by application of the cut points outlined above) have been specifically associated
with the postprandial distress syndrome subtype of FD in adults [36]. Duodenal biopsies from
adults with FD also have revealed more extensive degranulation, including documentation of
extracellular major basic protein; this corresponds to a similar finding of degranulation and
release of major basic protein previously demonstrated in pediatric patients with FD [33,35].
Although no information is available for healthy children, tissue eosinophilia has been
evaluated in the broad group of children with chronic abdominal pain, which provides some
limited basis for comparison. In a study of 1191 children with chronic abdominal pain,
eosinophilia was identified in the antrum or duodenum in 11.4% [37]. In another study, gastric
eosinophilia was reported in 19% and duodenal eosinophilia in 32% of children with unspe‐
cified chronic abdominal pain [19]. In contrast, duodenal eosinophilia has been demonstrated
in 79% of children specifically fulfilling FD criteria [38].
Antral eosinophil density does not appear to have any direct relationship to gastric electro‐
mechanical function in children with FD [28]. However, in patients with elevated mucosal
eosinophils, antral CD3+ cell density does correlate with preprandial tachygastria, indicating
that it may result from the interaction between different cell types [28].
3. Specific Conditions Associated with Mucosal Inflammation
There are a number of triggers or inciting events which may initiate an inflammatory response
in the gastrointestinal tract, particularly with regard to recruitment and activation of mast cells
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and eosinophils. These include stress/anxiety, infection (including H. pylori), and allergy, as
detailed below.
3.1. Stress/Anxiety
The involvement of inflammation in the biopsychosocial model is best illustrated by examining
the stress response. Corticotropin releasing hormone (CRH), produced by the hypothalamus
(as well as immune cells including lymphocytes and mast cells) is a major mediator of the stress
response in the hypothalamic-pituitary-adrenal axis and, subsequently, within the brain-gut
axis. CRH has central nervous system (CNS) effects which may alter central processing of
nociceptive messages, leading to anxiogenic and depressive effects. The stress response also
results in physiologic effects which may be relevant to FGIDs, including inflammation and
alterations of sensorimotor function such as altered gastric accommodation, gastric dysmotil‐
ity, and visceral hypersensitivity.
The relationship between the CNS and gastrointestinal pathophysiology appears bidirectional.
In a rodent model, gastric irritation in the neonatal period induces a long lasting increase in
depression- and anxiety-like behaviors. This, in turn, is associated with an increased expres‐
sion of CRH in the hypothalamus and increased sensitivity of the hypothalamic-pituitary-
adrenal axis to stress [39]. CRH stress systems may be activated by afferent nerves from
inflamed sites or via cytokines including TNF-α, IL-1, IL-6, and IL-12 [40]. The majority of
studies support an enhanced hypothalamic-pituitary-adrenal axis in at least some adults with
IBS, although results have been variable [41-45].
Corticotropin releasing hormone receptors are widely expressed including within the gastro‐
intestinal tract and immune cells. Mast cells express both CRH1 and CRH2 receptor subtypes
at their surface [46]. Most of the inflammatory cell actions, including those on mast cells, occur
via CRH2 receptors. Once mast cells are activated, they release mediators which recruit and
activate eosinophils. Both of these cell types are interactive in a bi-directional fashion with T
helper cells (Th; see Figure 2).
In addition to this indirect pathway, there also may be a direct effect for CRH on eosinophils.
In a rodent model, psychologic stress results in eosinophils expressing CRH [47]. CRH is not
expressed on eosinophils in the intestines of the mice except under psychologic stress and
decreases after the stress is removed, with the reversion requiring longer periods of time as
the length of the stressor increases [47]. A high correlation exists between anxiety scores and
mucosal eosinophil density in children with FD [48]. Antral mast cell density also correlates
with anxiety scores in children with FD [5]. Stress appears to shift the relative proportion and
trafficking of T helper lymphocytes towards a Th2 or “allergic” phenotype [40]. This shift is
driven by central and peripheral CRH, catecholamines, and histamine via H2 receptors. The
Th2 phenotype is associated with release of IL-4, IL-10, and IL-13, which stimulate growth and
activation of mast cells and eosinophils [40]. Shifting from a Th1 to a Th2 response may be the
mechanism through which low grade inflammation leads to visceral sensitivity and motility
disturbances; eosinophils and mast cells represent the key effector cells [49].
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Once activated by CRH, mast cells may release pre-formed and newly synthesized cytokines,
including interleukins (IL-4, IL-5, IL-6) and tumor necrosis factor (TNF-α) among others
[50,51]. In adults, there is selective luminal release of tryptase and histamine from jejunal mast
cells under cold stress; the magnitude of release is similar to that induced by antigen exposure
in food allergic patients [52]. Once released, mast cell and eosinophil mediators can stimulate
afferent nerves sending a “pain” message, sensitize afferent nerves resulting in visceral
hypersensitivity, and alter electromechanical function (see Figure 2). Histamine also can
stimulate afferent sensory nerves via H2 receptors [53]. Consistent with this, experimental
anxiety decreases gastric compliance and accommodation and increases epigastric symptom
scores during a standard nutrient challenge [54].
3.2. Infection
FD has been reported at a higher prevalence following both bacterial and parasitic infections
[55]. It seems likely that FD may also be induced by viral gastroenteritis similar to what has
been reported with IBS. In a large cohort of adults that were evaluated 8 years after bacterial
Figure 2. The Relationship between CRH Activation and Inflammatory Cells in FD Symptom Generation
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dysentery, an increased prevalence of FD was found compared to non-infected controls [56].
Consistent with the biopsychosocial model, anxiety and depression were independent risk
factors for developing post-infectious FD [56]. In another study, 82 adults were identified with
persistent abdominal symptoms following Giardia infection; 24.3% of these met criteria for FD,
while 80.5% met criteria for IBS [57]. Over half of these patients reported exacerbation due to
specific foods and nearly half reported exacerbations with physical or mental stress [57]. Rates
of post-infectious FD appear similar in pediatric populations. In a study of 88 children with a
previous positive bacterial stool culture, FD was present in 24% and IBS in 87% [58]. Fifty-six
percent of these patients reported the onset of abdominal pain after the acute infection.
Post-infectious FD appears to represent an impaired ability to terminate the inflammatory
response after the offending pathogen has been eliminated, but also may involve neuroplastic
changes in visceral and central afferent pathways as it is associated with impaired accommo‐
dation and increased sensitivity to distension [59-61]. Post-infectious FD patients frequently
demonstrate histologic duodenitis, with a severe grade in 57% [62]. Post-infectious FD is
associated with increased macrophages and may be associated with increased CD8+ cells [62,
63]. Findings regarding CD8+ cells however have been variable [62,63]. Duodenal eosinophilia
has also been described in post-infectious FD [49]. In addition, gastric mast cells are signifi‐
cantly increased in post-infectious FD as compared to healthy controls [64]. Post-infectious FD
is associated with increased gastric release of histamine and 5HT, as well as increased number
of mast cells within 5 μm of nerve fibers as compared to healthy controls or patients with FD
that is not post-infectious [64].
H. pylori. The role of Helicobacter pylori (H. pylori) in FD remains incompletely defined and,
as such, deserves particular attention within the scope of infectious organisms. Given that most
people never demonstrate symptoms at all when colonized with H. pylori, it is possible that
H. pylori has little to no contributory value for a significant subset of the population with FD.
However, it is possible that H. pylori may generate symptoms as a primary chronic infection
or, alternatively, patients may experience post-infectious FD once H. pylori has cleared in the
much the same way as seen in other bacterial and parasitic infections.
Several studies have demonstrated efficacy in reducing FD symptoms with H. pylori eradica‐
tion; however, others have found only a moderate (but statistically significant) effect or no
clinical benefit to eradication at all [65-69]. A Cochrane review concluded that eradication was
significantly better than placebo [69]. Response rates may be dependent on the specific
symptom. For example, one study documented a positive response to H. pylori eradication,
but only for the symptoms of epigastric pain and burning, indicating that efficacy may be
restricted to patients with the epigastric pain syndrome subtype of FD [67]. A large number
of patients with FD continue to experience symptoms following H. pylori eradication. These
may be patients in whom H. pylori had no pathologic role, or may represent a group of patients
who should be classified as post-infectious FD given that complete resolution of submucosal
inflammation requires a prolonged period [70].
H. pylori colonization is generally associated with gastric and duodenal histologic inflamma‐
tion. Histologic duodenitis has been associated with more severe symptoms when histologic
gastritis also is present [71]. However, this finding has not been consistent, with others actually
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reporting an inverse relation between severity of symptoms and gastric inflammation [72]. H.
pylori colonization in children is associated with increased mucosal lymphocytes, plasma cells,
neutrophils, and eosinophils, which decrease with eradication [20]. H. pylori colonization may
also be associated with increased antral mast cell density, though this may be H. pylori strain
specific [73]. In the setting of nodular gastritis associated with HP colonization, eosinophils
may be of particular significance. Nodularity is associated with the presence and density of
eosinophils [74]. Patients with nodular gastritis have a higher incidence of FD symptoms which
resolve with eradication therapy and improvement of gross endoscopic appearance [70]. Even
in the absence of nodularity, H. pylori colonization is associated with increased antral
eosinophils, as well as increased gastric fluid eosinophil cationic protein indicating eosino‐
philic activation [20,75,76]. These findings suggest a possible pathophysiologic role for
eosinophils in contributing to symptoms in patients with H. pylori colonization or possibly
following eradication.
Similar to post-infectious FD, H. pylori may be associated with electromechanical dysfunction
which, in turn, can contribute to FD symptom generation. Though studies are conflicting, H.
pylori has not consistently been associated with delayed gastric emptying or visceral hyper‐
sensitivity [77]. However, treatment with a prokinetic was found to be as effective as eradica‐
tion at 12 months [78]. H. pylori also has been associated with an abnormal electrogastrogram
that normalized in 83% with eradication [79]. H. pylori does not appear to have any effect on
accommodation [60].
3.3. Allergy
The role of allergy in the development of FD has not been greatly studied. However, allergy
may be important given the observed increases in, and activation of, mast cells and eosinophils
in FD. FGIDs occur more commonly in children with a history of cow’s milk allergy as infants
[80]. In children with FD in association with cow’s milk allergy, mucosal application of cow’s
milk is associated with increased eosinophils and mast cells, as well as rapid degranulation,
within 10 minutes of application [81]. In addition, cow’s milk exposure is associated with
increased mast cells within 5 μm of nerves [81]. Adult FD patients with a history of allergy
have increased duodenal eosinophil density [36]. In addition, lymphoid hyperplasia is
significantly more frequent in children with abdominal pain associated with food allergies [19].
Lymphoid hyperplasia is associated with food hypersensitivity although this reaction may be
local reactivity only as it is associated with normal skin prick tests and normal serum IgE levels
[82,83].
Food allergy, similar to post-infectious FD and H. pylori colonization, also may cause electro‐
mechanical dysfunction. Exposure to cow’s milk in allergic FD children resulted in increased
bradygastria [81]. In infants with cow’s milk allergy, exposure results in gastric arrhythmias
and delayed gastric emptying [84].
Whether food allergy accounts for a substantial portion of children with FD is not clear. One
study found no significant increase in immunoreactivity to common food allergens in FD
children with duodenal eosinophilia, although it is possible that the reaction was localized to
the mucosa [85]. It is also possible that environmental allergens may be playing a role. Antigen
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exposure in adults with birch pollen allergy results in an increase in mucosal major basic
protein positive eosinophils and IgE-bearing cells, as well as in FD symptoms, in the majority
of patients [86]. Information in this area remains quite limited.
4. Implications for Care
4.1. Evaluation
The current approach to the pediatric FD patient has not been thoroughly studied. Based on
existing small studies in children and large studies in adults, however, it appears reasonable
to treat empirically with acid reducing medications and proceed with endoscopy with biopsies
for non-responders. There may be value in evaluating mucosal biopsies for eosinophil density,
particularly those obtained from the duodenum. A reasonable standard would be to consider
antral eosinophil density >10/hpf and duodenal eosinophil density >20/hpf as abnormal.
Despite current information implicating a role for mucosal mast cells, particularly in the
antrum, it is less clear if there is value in determining mast cell density. The latter would require
special immunohistochemical stains and the standard for normal is even less well defined than
for eosinophils.
4.2. Treatment
Medications targeting mast cells or eosinophils could offer benefit by decreasing either cell
density or activation. Such agents include corticosteroids and mast cell stabilizers. In addition,
medications potentially could provide relief by targeting receptors for specific mediators once
released by either cell. Although there is no current means for identifying the specific media‐
tors generating symptoms in a particular patient, antagonists are available for some mediators,
such as histamine, cysteinyl leukotrienes, and TNF- α. Finally, other treatments exist that may
provide relief by targeting other factors, such as CRH, that may play an important role in
activation and/or maintenance of inflammation. Consistent with a biopsychosocial model,
combining treatments that address inflammation from different perspectives ultimately
should be most beneficial.
Corticosteroids. Corticosteroids have not been evaluated in treating FD, but are commonly used
in the treatment of eosinophilic gastroenteritis, although there are no placebo-controlled
studies evaluating efficacy. The extensive side effect profile represents a significant draw back
in considering their use long term. Budesonide may represent a safer alternative. Budesonide
is a synthetic corticosteroid with high topical activity and substantial first pass elimination,
limiting systemic exposure [87]. The literature regarding budesonide and eosinophilic
gastroenteritis is limited, consisting of only case reports where budesonide therapy has been
reported to be effective against eosinophilia in the duodenum and jejunum [88-90].
Mast Cell Stabilizers. Mast cell stabilizers, including cromolyn and ketotifen, would represent
an attractive potential therapy given data implicating mast cells in the generation of FD
symptoms as previously discussed. These agents would have the potential to prevent release
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of a variety of mediators with downstream effects. In one open-label observational study of
children with FD in association duodenal eosinophilia, resolution of pain was demonstrated
with use of oral cromolyn in 89% of patients who had previously failed to respond to H2 and
combined H1/H2 antagonism [91]. There have been no other pediatric or adult studies on the
use of mast cell stabilizers in patients with FD. Benefit has been demonstrated in adults with
IBS and may be related to blocking allergic or immunologic reactions to foods [92-94].
Ketotifen, specifically, has been shown to significantly decrease pain in adults with IBS and to
increase the threshold for discomfort in patients with visceral hypersensitivity [95]. Ketotifen
also acts as an H1 antagonist, so the effects may not be directly, or completely, related to mast
cell stabilization.
Antihistamine Medications and Proton Pump Inhibitors (PPI). Acid reduction remains the most
common treatment prescribed empirically by pediatric gastroenterologists for children with
FD [9]. While there are numerous adult studies to support this practice, pediatric studies are
limited. In children with chronic abdominal pain, famotidine (H2 recptor antagonist - H2RA)
was superior to placebo in global improvement, with clear benefit to those with FD [96]. In a
large pediatric study, omeperazole was shown to have a very modest advantage in the relief
of all symptoms as compared to either famotidine or ranitidine; however, there was no
significant difference between the three with regard to resolution of abdominal pain, epigastric
pain, nausea, or vomiting specifically [97].
In adults, H2 antagonism has been shown to improve at least some symptoms associated with
FD, including abdominal pain, indigestion, belching, and gastroesophageal reflux symptoms
[98,99]. H2 antagonists have been shown to be superior to prokinetic medications and short
term use of an anxiolytic [100,101]. A meta-analysis evaluating the use of PPIs in adult FD
determined that they were superior to placebo in symptom reduction [102]. Studies of
omeperazole, lansoprazole, and pantoprazole have demonstrated a modest superiority to
placebo in symptom reduction which is limited to patients with ulcer-like or reflux-like FD
[103-105]. Whether PPIs are superior to H2 antagonism is not completely clear. Omeperazole
was found to have a modest increase in efficacy as compared to ranitidine at 4 weeks (51% vs.
36%), but there was no additional benefit at 6 months [101].
Given the response to PPIs, it would appear that at least some of the clinical improvement
from H2 antagonism or PPIs is related directly to acid suppression. A significant portion of
responders may derive benefit from treatment of overlap GERD, or possibly from peptic
gastritis or duodenitis. Conversely, the benefit may be due to removing exposure to acid in
patients with acid hypersensitivity. PPIs do not appear to have other benefits with regard to
gastric emptying or myoelectrical function [106].
The benefit of H2 antagonism may be unrelated to acid reduction, at least in part. Histamine
has direct gastric myogenic actions, modulates afferent enteric nerve excitability, and acts as
an immunomodulating agent [53,107-111]. There may be additional benefit from H1 antago‐
nism, as well. Combining an H1 antagonist with an H2 antagonist has been reported to relieve
symptoms in 50% of children with FD associated with duodenal eosinophilia and in 79% of
adults with FD associated with increased antral mast cell density who had previously failed
to respond to acid reduction therapy [91,112]. H1 receptors affect smooth muscle contraction
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and visceral sensitivity [53]. In addition, some benefit from H1 antagonism may be due to an
anxiolytic effect [113].
Cysteinyl Leukotriene (cysLT) Antagosists. CysLTs are another potential therapeutic target. The
pattern of eosinophil degranulation in pediatric FD is consistent with the release of major basic
protein, which is known to enhance the synthesis of cysLT; cysLT, in turn, stimulates smooth
muscle contraction and recruitment of eosinophils [114]. CysLTs have been shown to alter mast
cell function. CysLTs can induce IL-5 and TNF-α production in primed mast cells, an effect
blocked by cysLT inhibition [115]. Leukotrienes (LTs) have the potential to increase intestinal
sensory nerve sensitivity during inflammation. CysLTs have been shown to stimulate enteric
neurons and to have a pro-contactile effect on the esophagus, stomach, small intestine, colon,
and gallbladder [116-123].
Montelukast, a cysLT receptor antagonist, was superior to placebo with regard to relief of pain
in a double-blind, placebo-controlled, cross-over trial of children with FD associated with
duodenal eosinophilia [124]. The response rate was 84% in patients with eosinophil densities
between 20 and 29/hpf versus 42% receiving placebo. A second study confirmed this high
response rate [125]. In the latter study, the short term clinical response did not result from a
decrease in eosinophil density or activation. This suggests that the effect of montelukast may
be mediated through an enteric nerve effect on motility or sensitivity, something that remains
to be demonstrated.
Anti-TNF-α. TNF-α would represent another potential therapeutic target. Mast cells are an
important source of intestinal mucosal TNF-α in humans. CysLTs induce TNF-α production.
TNF-α can recruit and prolong survival of eosinophils, as well promote a Th2 response
depending on other chemokines present in the microenvironment [126-128]. Serum TNF-α
concentration prior to treatment correlates negatively with the subsequent clinical response to
montelukast in pediatric FD associated with duodenal eosinophilia, indicating that TNF-α may
represent an alternative pathway for symptom generation in these patients. Although there
are no controlled studies, anti-TNF-α has been reported to be effective in a series of children
with resistant eosinophil disease, including patients with FD [129].
Biofeedback-Assisted Relaxation Training. The biopsychosocial model and CRH physiology
would suggest a potential role for CRH antagonism or for controlling CRH secretion by
controlling anxiety and the stress response. There are no previous studies evaluating CRH-
antagonists in FD. Stress management would have the potential to control CRH secretion and,
thereby, decrease inflammation. Biofeedback is a technique where individuals are trained to
relieve physical or emotional symptoms using signals from their bodies that are displayed
visually or aurally. It can be paired with relaxation training to yield biofeedback-assisted
relaxation training. Biofeedback-assisted relaxation training may be considered as a solo
therapy or, consistent with the biopsychosocial model, a stronger effect may occur in combin‐
ing relaxation with medications targeting biologic factors such as inflammation. The combi‐
nation of biofeedback-assisted relaxation training and fiber is superior to fiber alone in children
with non-specific abdominal pain [130]. The effect of biofeedback-assisted relaxation training
on inflammation has not been studied directly, but biofeedback-assisted relaxation training
has been studied as adjunctive treatment in children with FD in association with duodenal
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eosinophilia [131]. Children receiving medication plus biofeedback-assisted relaxation
training demonstrated better outcomes with regard to pain intensity, duration of pain
episodes, and global clinical improvement as compared to children receiving medications
alone [131].
5. Conclusions
Current evidence implicates inflammation, particularly mast cells and eosinophils, in the
pathophysiology of FD. FD in adults is associated with an increase in antral mast cell density
and an increase in duodenal eosinophil density; elevated duodenal eosinophil density is
frequently present in children with FD. Active degranulation of both cell types in children with
FD suggests a pathophysiologic role. In children with FD, higher antral mast cell density is
associated with gastric electromechanical dysfunction, psychologic dysfunction, and symp‐
toms consistent with the postprandial distress syndrome subtype of FD defined for adults.
Duodenal eosinophil density appears associated with anxiety in children with FD, but
relationships with electromechanical dysfunction appear less direct. Both mast cells and
eosinophils may have key roles in conditions that are associated with FD, including anxiety,
infection (including H. pylori), and allergy. Ultimately, inflammation appears to be of
particular importance in FD. Inflammation interacts with a number of other factors and may
even mediate the relationship between psychologic and physiologic factors.
There may be efficacy in utilizing medications directed at inflammation, particularly mast cells
and eosinophils. Most reports on treatment response consist of case series using H1/H2
antagonists, mast cell stabilizers, and anti-TNF-α. Consistent with a biopsychosocial model,
some evidence exists to suggest that combining treatments targeting different components of
the model that may influence inflammation can increase rates of symptom resolution in
pediatric FD. There remains a need for placebo-controlled trials of the various medications
and other treatments targeting inflammation which have been suggested to have efficacy, both
alone and in thoughtful combination. Treatment for pediatric FD must continue to evolve if
we are to prevent the significant downstream costs to the individual and society and, in this
goal, inflammation appears an important primary target.
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